Skip to main content Back to Top
Advertisement

5/17/2016

Aminocaproic Acid Oral Presentations

Products Affected - Description

    • Aminocaproic Acid oral solution, Akorn, 0.25 gram/mL, 237 mL bottle, NDC 61748-0044-08
    • Aminocaproic Acid oral solution, Akorn, 0.25 gram/mL, 437 mL bottle, NDC 61748-0044-16
    • Aminocaproic Acid oral tablet, Akorn, 1000 mg, 100 count, NDC 61748-0046-01
    • Aminocaproic Acid oral tablet, Akorn, 500 mg, 100 count, NDC 61748-0045-01
    • Aminocaproic Acid oral tablet, Akorn, 500 mg, 10 X 10 blister card NDC 61748-0045-11

Reason for the Shortage

    • Akorn acquired Versapharm in 2014.
    • Akorn stopped distributing and marketing Versapharm's aminocaproic acid product on June 22, 2015.
    • Akorn launched Amicar oral solution and tablets on June 29, 2015.

Available Products

    • Amicar oral solution, Akorn, 0.25 gram/mL, 237 mL bottle, NDC 49411-0052-08
    • Amicar oral tablet, Akorn, 1000 mg, 30 count, NDC 49411-0051-30
    • Amicar oral tablet, Akorn, 500 mg, 30 count, NDC 49411-0050-30

Estimated Resupply Dates

    • Akorn has Amicar tablets and oral solution available.

Updated

Updated May 17, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 2, 2015 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins